Jane Street Group, LLC Dia Medica Therapeutics Inc. Transaction History

Jane Street Group, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.16 - $3.66 $317 - $538	-147 Reduced 0.96%	15,091 $44,000
Q1 2024 May 15, 2024	SELL	$2.58 - $3.23 $21,989 - $27,529	-8,523 Reduced 35.87%	15,238 $42,000
Q4 2023 Feb 14, 2024	BUY	$2.05 - $2.99 $48,710 - $71,045	23,761 New	23,761 $67,000
Q4 2022 Feb 14, 2023	BUY	$1.13 - $1.62 $12,245 - $17,555	10,837 Added 108.34%	20,840 $32,000
Q3 2022 Nov 14, 2022	BUY	$1.2 - $2.07 $12,003 - $20,706	10,003 New	10,003 $12,000
Q3 2022 Nov 14, 2022	BUY	$1.2 - $2.07 $12,003 - $20,706	10,003 New	10,003 $12,000
Q1 2021 May 18, 2021	SELL	$7.76 - $10.43 $97,287 - $130,760	-12,537 Closed	0 $0
Q4 2020 Feb 17, 2021	BUY	$4.13 - $10.14 $51,777 - $127,125	12,537 New	12,537 $127,000

4.22M

8.2K

200

Ticker DMAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,443,100
Market Cap $128M
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.